Abstract: A JAK kinase inhibitor and use thereof. The JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof. Further, the use of the compound of formula I in preparation of drugs for preventing or treating JAK kinase-related diseases, especially in preparation of drugs for preventing and/or treating diseases involving cartilage degradation and bone and/or joint degradation, conditions involving inflammation or immune response, endotoxin-driven disease states, cancer, and organ transplantation rejection.

Abstract: The present invention relates to a modulator of 1,2,5-oxadiazole indoleamine-(2,3)-dioxygenase, a preparation method and use thereof, more particularly to compounds of Formula I and Formula II, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, and their use in preparing drugs for treating cancers, neurodegenerative diseases, eye diseases, mental disorders, depression, anxiety disorders, Alzheimer's diseases and/or autoimmune diseases. Specific meanings of R substituents in Formula I and Formula II are consistent with the description of the specification.

Abstract: The present invention relates to a new pyrrole sulfonyl derivative, and a preparation method and medical use thereof. In particular, the present invention relates to a pyrrole sulfonyl derivative as represented by general formula (I), a preparation method thereof, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, in particular as a gastric acid secretion inhibitor and as potassium-competitive acid blockers (P-CABs), wherein each substituent group of general formula (I) is the same as that defined in the description.

Abstract: The present invention relates to a modulator of 1,2,5-oxadiazole indoleamine-(2,3)-dioxygenase, a preparation method and use thereof, more particularly to compounds of Formula I and Formula II, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, and their use in preparing drugs for treating cancers, neurodegenerative diseases, eye diseases, mental disorders, depression, anxiety disorders, Alzheimer's diseases and/or autoimmune diseases. Specific meanings of R substituents in Formula I and Formula II are consistent with the description of the specification.

Abstract: The invention relates to a 4-substituted pyrrolo[2,3-d]pyrimidine compound and the use thereof in preparing medications for treating JAK-targeted diseases such as rheumatoid, immune system diseases, and tumor. The 4-substituted pyrrolo[2,3-d]pyrimidine compound of the invention is as shown in chemical formula I. The activity experimental results of the invention show that the new compound has obvious effect and activity in inhibition of Janus kinases, JAK-STAT, cell proliferation of human lymphocytoma, and rheumatoid arthritis.

Abstract: The present invention relates to a new pyrrole sulfonyl derivative, and a preparation method and medical use thereof. In particular, the present invention relates to a pyrrole sulfonyl derivative as represented by general formula (I), a preparation method thereof, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, in particular as a gastric acid secretion inhibitor and as potassium-competitive acid blockers (P-CABs), wherein each substituent group of general formula (I) is the same as that defined in the description.

Abstract: The invention relates to a 4-substituted pyrrolo[2,3-d]pyrimidine compound and the use thereof in preparing medications for treating JAK-targeted diseases such as rheumatoid, immune system diseases, and tumor. The 4-substituted pyrrolo[2,3-d]pyrimidine compound of the invention is as shown in chemical formula I. The activity experimental results of the invention show that the new compound has obvious effect and activity in inhibition of Janus kinases, JAK-STAT, cell proliferation of human lymphocytoma, and rheumatoid arthritis.